User profiles for Marina Treskova-Schwarzbach
 | Marina TreskovaJunior Group Leader, Post-doctoral scientist. Climate-Sensitive Infectious Diseases Lab … Verified email at uni-heidelberg.de Cited by 1022 |
[HTML][HTML] Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B. 1.617. 2) variant: second interim results of a living systematic review and …
…, S Reda, M Treskova-Schwarzbach… - …, 2021 - eurosurveillance.org
The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the
evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE …
evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE …
[HTML][HTML] Post-COVID-19-associated morbidity in children, adolescents, and adults: a matched cohort study including more than 157,000 individuals with COVID-19 in …
…, JP Armann, R Berner, M Treskova-Schwarzbach… - PLoS …, 2022 - journals.plos.org
Background Long-term health sequelae of the Coronavirus Disease 2019 (COVID-19) are a
major public health concern. However, evidence on post-acute COVID-19 syndrome (post-…
major public health concern. However, evidence on post-acute COVID-19 syndrome (post-…
[HTML][HTML] Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
M Treskova-Schwarzbach, L Haas, S Reda, A Pilic… - BMC medicine, 2021 - Springer
Background This study applies an umbrella review approach to summarise the global evidence
on the risk of severe COVID-19 outcomes in patients with pre-existing health conditions. …
on the risk of severe COVID-19 outcomes in patients with pre-existing health conditions. …
Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19
…, JP Armann, R Berner, M Treskova-Schwarzbach… - MedRxiv, 2021 - medrxiv.org
Background Long-term health sequelae of the coronavirus disease 2019 (COVID-19) are a
major public health concern. However, evidence on post-acute COVID-19 syndrome (post …
major public health concern. However, evidence on post-acute COVID-19 syndrome (post …
[HTML][HTML] Determinants of RSV epidemiology following suppression through pandemic contact restrictions
…, E van Leeuwen, M Treskova-Schwarzbach… - Epidemics, 2022 - Elsevier
Introduction COVID-19 related non-pharmaceutical interventions (NPIs) led to a suppression
of RSV circulation in winter 2020/21 in the UK and an off-season resurgence in Summer …
of RSV circulation in winter 2020/21 in the UK and an off-season resurgence in Summer …
[HTML][HTML] Population with an increased risk of severe COVID-19 in Germany. Analyses from GEDA 2019/2020-EHIS
…, M Treskova-Schwarzbach… - Journal of Health …, 2021 - ncbi.nlm.nih.gov
Only a minority of people who test positive for COVID-19 develop a severe or critical form of
the disease. Many of these have risk factors such as old age or pre-existing conditions and, …
the disease. Many of these have risk factors such as old age or pre-existing conditions and, …
[HTML][HTML] Development of a risk score to identify patients at high risk for a severe course of COVID-19
…, R Jucknewitz, M Treskova-Schwarzbach… - Journal of Public …, 2023 - Springer
Aim We aimed to develop a risk score to calculate a person’s individual risk for a severe
COVID-19 course (POINTED score) to support prioritization of especially vulnerable patients for …
COVID-19 course (POINTED score) to support prioritization of especially vulnerable patients for …
Beschlussentwurf der STIKO zur 4. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung
…, S Scholz, M Terhardt, M Treskova-Schwarzbach… - 2021 - edoc.rki.de
Die STIKO empfiehlt die Impfung gegen COVID-19 mit einem der beiden zugelassenen
mRNA-Impfstoffe (Comirnaty von BioNTech/Pfizer, COVID-19-Vaccine von Moderna) oder …
mRNA-Impfstoffe (Comirnaty von BioNTech/Pfizer, COVID-19-Vaccine von Moderna) oder …
Beschluss und wissenschaftliche begründung der ständigen impfkommission (STIKO) für die COVID-19-impfempfehlung
…, S Scholz, M Terhardt, M Treskova-Schwarzbach… - 2020 - edoc.rki.de
Die im Epidemiologischen Bulletin 2/2021 veröffentlichte Empfehlung tritt in Kraft, sobald
ein erster Impfstoff zum Schutz vor COVID-19 zugelassen und in Deutschland verfügbar ist. …
ein erster Impfstoff zum Schutz vor COVID-19 zugelassen und in Deutschland verfügbar ist. …
Estimating RSV seasonality from pandemic disruptions: a modelling study
Background Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infections
and bronchiolitis in young children. The seasonal pattern of RSV is shaped by short-lived …
and bronchiolitis in young children. The seasonal pattern of RSV is shaped by short-lived …